{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=12", "query": { "intervention": "Dose level 3", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 17825, "total_pages": 1783, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T17:16:48.065Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05141357", "title": "A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "HBI-8000 in combination with pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HUYABIO International, LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2022-02-15", "completion_date": "2023-04-19", "has_results": true, "last_update_posted_date": "2025-12-24", "last_synced_at": "2026-11-12T17:16:48.065Z", "location_count": 7, "location_summary": "Goodyear, Arizona • Bakersfield, California • Port Saint Lucie, Florida + 4 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Newnan", "state": "Georgia" }, { "city": "Zion", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05141357" }, { "nct_id": "NCT05442775", "title": "A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Amyotrophic Lateral Sclerosis" ], "interventions": [ { "name": "Reldesemtiv", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cytokinetics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2022-08-04", "completion_date": "2023-06-07", "has_results": true, "last_update_posted_date": "2024-08-13", "last_synced_at": "2026-11-12T17:16:48.065Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Orange, California • San Francisco, California + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05442775" }, { "nct_id": "NCT05019430", "title": "Cocaine and Zolmitriptan", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Cocaine Use Disorder" ], "interventions": [ { "name": "Cocaine", "type": "DRUG" }, { "name": "Placebo oral capsule", "type": "DRUG" }, { "name": "Zolmitriptan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "William Stoops", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 12, "start_date": "2021-10-15", "completion_date": "2025-01-09", "has_results": true, "last_update_posted_date": "2025-08-05", "last_synced_at": "2026-11-12T17:16:48.065Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05019430" }, { "nct_id": "NCT01925612", "title": "Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, B-cell", "Lymphoma, Large B-cell, Diffuse" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2013-08", "completion_date": "2017-05-01", "has_results": true, "last_update_posted_date": "2018-06-21", "last_synced_at": "2026-11-12T17:16:48.065Z", "location_count": 36, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01925612" }, { "nct_id": "NCT00607828", "title": "Stereotactic Radiation Therapy in Treating Patients With Advanced Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "stereotactic body radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "19 Years to 120 Years" }, "enrollment_count": 7, "start_date": "2007-11-16", "completion_date": "2017-02-15", "has_results": true, "last_update_posted_date": "2024-11-04", "last_synced_at": "2026-11-12T17:16:48.065Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00607828" }, { "nct_id": "NCT00393965", "title": "Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Neoplasms" ], "interventions": [ { "name": "MPC-6827", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myrexis Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2005-12", "completion_date": "2008-02", "has_results": false, "last_update_posted_date": "2008-02-13", "last_synced_at": "2026-11-12T17:16:48.065Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00393965" }, { "nct_id": "NCT00005800", "title": "Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "18 Years to 70 Years · Female only" }, "enrollment_count": 45, "start_date": "1999-04", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2012-09-25", "last_synced_at": "2026-11-12T17:16:48.065Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005800" }, { "nct_id": "NCT01904136", "title": "Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Acute Myeloid Leukemia With Gene Mutations", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "de Novo Myelodysplastic Syndrome", "Myelodysplastic Syndrome", "Recurrent Acute Myeloid Leukemia", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Therapy-Related Acute Myeloid Leukemia" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Bone Marrow Transplantation", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Natural Killer Cell Therapy", "type": "BIOLOGICAL" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "2 Years to 65 Years" }, "enrollment_count": 54, "start_date": "2014-04-22", "completion_date": "2022-02-28", "has_results": true, "last_update_posted_date": "2024-01-24", "last_synced_at": "2026-11-12T17:16:48.065Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01904136" }, { "nct_id": "NCT01715051", "title": "D-Serine for Cocaine Dependence Pilot", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cocaine Dependence" ], "interventions": [ { "name": "D-serine", "type": "DRUG" }, { "name": "Cognitive Behavioral Therapy", "type": "BEHAVIORAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Theresa Winhusen", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-02", "completion_date": "2019-09", "has_results": false, "last_update_posted_date": "2014-02-06", "last_synced_at": "2026-11-12T17:16:48.065Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01715051" }, { "nct_id": "NCT00369629", "title": "Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2006-08-28", "completion_date": "2013-06-04", "has_results": true, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-11-12T17:16:48.065Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00369629" } ] }